WO2006064539A1 - 還元性生理食塩水及びその製造方法 - Google Patents
還元性生理食塩水及びその製造方法 Download PDFInfo
- Publication number
- WO2006064539A1 WO2006064539A1 PCT/JP2004/018601 JP2004018601W WO2006064539A1 WO 2006064539 A1 WO2006064539 A1 WO 2006064539A1 JP 2004018601 W JP2004018601 W JP 2004018601W WO 2006064539 A1 WO2006064539 A1 WO 2006064539A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- physiological saline
- hydrogen gas
- reducing
- pressure
- saline solutions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
Definitions
- the invention of this application relates to a novel physiological saline and a method for producing the same. More details
- the invention of this application relates to a physiological saline containing hydrogen, and relates to a novel reducing physiological saline having a low redox potential and a method for producing the same.
- alkaline ionized water is good for health, various diseases caused by active oxygen and lipid peroxide (eg, stroke, myocardial infarction, arteriosclerosis, cancer, hyperlipidemia, diabetes, hepatitis , Nephritis, ulcer, gastric mucosal disorder, pneumonia, cataract, retinitis pigmentosa, retinal detachment, collagen disease and other autoimmune diseases, rheumatoid arthritis, AIDS, Parkinson's disease, Alzheimer's disease, atopic dermatitis, hay fever, etc.
- active oxygen and lipid peroxide eg, stroke, myocardial infarction, arteriosclerosis, cancer, hyperlipidemia, diabetes, hepatitis , Nephritis, ulcer, gastric mucosal disorder, pneumonia, cataract, retinitis pigmentosa, retinal detachment, collagen disease and other autoimmune diseases, rheumatoid arthritis, AIDS, Parkinson's disease, Alzheimer's disease,
- alkaline ionized water electrolyzes tap water, saline or NaOH solution using an anode and a cathode, and forms acidic water on the anode side and alkaline water on the cathode side.
- alkaline water on the cathode side is used.
- This cathode-side alkaline water contains a lot of hydroxide ions (OH_), and also shows the reducibility because the hydrogen gas generated by water electrolysis is dissolved. It is called.
- the present invention relates to reduced water having a pH value of 9.0 or lower and 6.5 or higher and an oxidation-reduction potential of 1 15 OmV or lower and 900 mV or higher under normal temperature and normal pressure.
- Patent Document 1 Japanese Patent Application Laid-Open No. 2001-145880
- Patent Document 2 Japanese Patent Laid-Open No. 2001-137852
- Patent Document 3 Japanese Patent Laid-Open No. 2002-254078
- Patent Document 4 Japanese Patent Laid-Open No. 2004-230370
- physiological saline has been widely used for injection, for washing skin, wound surfaces, mucous membranes, etc., for bronchial mucosal washing such as phlegm and spray inhalation, and for promoting sputum discharge.
- the idea of verifying the physiological saline from the viewpoint of redox is not known.
- normal saline is manufactured and used by various methods.
- the redox potential is considered as a problem with respect to the physiological saline, and a low redox potential is given to the physiological saline, that is, the reducing potential is given. There is no way of thinking.
- Saline contains 154mEqZL of sodium ions and 154mEq / L of chloride ions in lOOOOmL, and is an aqueous solution with a normal pH value of 4.5-8.0. That is, if reducing physiological saline is obtained, various physiological activities as described above can be expected.
- the inventors of the present application have conducted various experiments to obtain a reducing physiological saline, and as a result, the normal temperature is then cooled to normal temperature under pressure to the cooled physiological saline.
- hydrogen gas is dissolved until it reaches an equilibrium state, and when the pressurized pressure is removed and the temperature is returned to normal temperature and normal pressure, a part of the hydrogen gas dissolved in the physiological saline vaporizes, but the number of normal solubility
- the hydrogen gas is almost double or hundreds of times dissolved, and the dissolved hydrogen gas is stably dissolved with almost no vaporization. It has been found that it has a reduction potential, and the present invention has been completed.
- the present invention provides a reducing physiological saline having a sufficient reducibility from a slightly alkaline region to a weakly acidic region having a pH value of 4.5 to 8.0 and a method for producing the same. For purposes.
- physiological saline having a redox potential of 10 mV or less and _2000 mV or more under normal temperature and normal pressure. Water is provided.
- physiological saline The lower the oxidation-reduction potential of physiological saline, the greater the ability to achieve a greater reducing ability. It is difficult to obtain a physiological saline having an oxidation-reduction potential of -lOOOmV or less, so -lOOOmV or more is desirable. If the redox potential of physiological saline is -10 mV or less, it shows a reducing power — if it is 150 mV or less, it shows better reducing ability.
- the pH value of the physiological saline solution of the present invention needs to be 4.5-8.0. This pH value is 4.
- this reducing physiological saline has an oxidation-reduction potential of _10mV or less and _2000mV or more. It can be expected not only an effect but also a physiological activity due to the reducing property.
- hydrogen gas at -180 ° C and 90 ° C is added to the physiological saline.
- a reducing physiological saline obtained by pressurizing and dissolving from 1 atm to 800 atm (gauge pressure, the same applies hereinafter) and returning to normal temperature and pressure is provided.
- a method for producing an effective physiological saline solution is provided.
- the hydrogen gas can be supplied in a batch type or a continuous flow type.
- the upper limit of the temperature of the hydrogen gas is set to 90 ° C because the hydrogen gas is normally supplied in a hydrogen gas cylinder, but the temperature of the hydrogen gas cylinder left outside is about 90 ° C. This is often the case, and even the hydrogen gas at this temperature can be sufficiently dissolved in the physiological saline of the raw material. This is because the solubility decreases, which is not preferable.
- the reason why the lower limit of the temperature of hydrogen gas is set to 180 ° C is that hydrogen gas may be supplied in the form of liquefied hydrogen cooled to _253 ° C or lower.
- the hydrogen temperature when dissolving in normal saline should be at least o ° c.
- the pressure at which hydrogen gas is dissolved in physiological saline is 0.1 atm to 1800 atm. The higher the pressure, the greater the amount of hydrogen gas dissolved in the physiological saline.
- the obtained physiological saline is finally returned to normal temperature and normal pressure. Since the amount of hydrogen that is vaporized when the gas is returned to a high level, it is wasted in terms of economy and energy.
- 0.5 to 10 atmospheres, more preferably 1 to 15 atmospheres are used.
- the rate of dissolution of hydrogen gas in physiological saline varies depending on the temperature and pressure when the hydrogen gas is dissolved, but is about 0.001 to 0.00 when the temperature is returned to normal temperature and pressure.
- About lwt% is stably dissolved. Solubility in water of hydrogen gas at ordinary temperature under normal pressure, since approximately 2 ml / 100 ml (about 1. 8 X 10- 4 wt%) , hydrogen gas amount of saline obtained by the present invention just normal temperature Compared to when hydrogen gas is dissolved under pressure, hydrogen gas is dissolved about 5 to 500 times.
- a well-known gas-liquid contact device can be used, and it can be used in either a batch type or a continuous flow type.
- the hydrogen gas vaporized when the physiological saline that has absorbed hydrogen gas at high pressure is returned to normal temperature and pressure can be recovered and reused.
- the pressure was adjusted to 6 atmospheres and the outlet pressure was 0.2 atmospheres, and a total of 1 liter was allowed to flow at a rate of 200 ml / min for 5 minutes using a gas-liquid contact device. Thereafter, the obtained reducing physiological saline was kept under normal pressure to obtain the reducing physiological saline according to the example, and the redox potential and pH value of this reducing physiological saline were measured.
- Table 1 The results are summarized in Table 1.
- the physiological saline to which hydrogen is not added has a pH value of 7.16, and the redox potential is +269 mV.
- the reducing physiological saline of the present invention has a pH value of Is slightly changed to 7. 25, and the redox potential is as low as 1 637 mV, indicating that a good reducing saline solution is obtained. I understand.
- the pH value needs to be 4.5 to 8.0 in order to match the pH value of physiological saline that is generally used. Reducing physiological saline having a redox potential of -10 mV or less can be obtained even when the pH value is 5 or less. In addition, the obtained reducing saline The lower limit of the oxidation-reduction potential decreases with increasing pH value, and can be as low as 900 mV or less.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2004/018601 WO2006064539A1 (ja) | 2004-12-13 | 2004-12-13 | 還元性生理食塩水及びその製造方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2004/018601 WO2006064539A1 (ja) | 2004-12-13 | 2004-12-13 | 還元性生理食塩水及びその製造方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006064539A1 true WO2006064539A1 (ja) | 2006-06-22 |
Family
ID=36587604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/018601 WO2006064539A1 (ja) | 2004-12-13 | 2004-12-13 | 還元性生理食塩水及びその製造方法 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2006064539A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3485872A1 (en) * | 2017-11-15 | 2019-05-22 | Jennifer Peters | Compositions comprising hyaluronic acid and h2 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000517311A (ja) * | 1996-08-27 | 2000-12-26 | メッサー グリースハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング | 水素含有薬剤 |
JP2001269393A (ja) * | 2000-03-24 | 2001-10-02 | Morinaga Milk Ind Co Ltd | 殺菌作用を有する生理食塩水、これを利用した洗浄消毒水、及びそれらの製造方法 |
JP2001314877A (ja) * | 2000-03-03 | 2001-11-13 | Aqua Science:Kk | 生体水に類似する水およびその製造法 |
JP2002018439A (ja) * | 1995-08-01 | 2002-01-22 | Matsuo Yoshiaki | ビタミンc入りアルカリ性電解水 |
JP2003012525A (ja) * | 2001-07-02 | 2003-01-15 | Hoshizaki Electric Co Ltd | 生体の損傷部位用の洗浄水およびその製造装置 |
JP2004099527A (ja) * | 2002-09-10 | 2004-04-02 | Meiji Yakuhin Kk | ポリフェノール添加生理食塩水 |
JP2004230370A (ja) * | 2002-12-05 | 2004-08-19 | Wataru Murota | 還元水及びその製造方法 |
-
2004
- 2004-12-13 WO PCT/JP2004/018601 patent/WO2006064539A1/ja not_active Application Discontinuation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002018439A (ja) * | 1995-08-01 | 2002-01-22 | Matsuo Yoshiaki | ビタミンc入りアルカリ性電解水 |
JP2000517311A (ja) * | 1996-08-27 | 2000-12-26 | メッサー グリースハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング | 水素含有薬剤 |
JP2001314877A (ja) * | 2000-03-03 | 2001-11-13 | Aqua Science:Kk | 生体水に類似する水およびその製造法 |
JP2001269393A (ja) * | 2000-03-24 | 2001-10-02 | Morinaga Milk Ind Co Ltd | 殺菌作用を有する生理食塩水、これを利用した洗浄消毒水、及びそれらの製造方法 |
JP2003012525A (ja) * | 2001-07-02 | 2003-01-15 | Hoshizaki Electric Co Ltd | 生体の損傷部位用の洗浄水およびその製造装置 |
JP2004099527A (ja) * | 2002-09-10 | 2004-04-02 | Meiji Yakuhin Kk | ポリフェノール添加生理食塩水 |
JP2004230370A (ja) * | 2002-12-05 | 2004-08-19 | Wataru Murota | 還元水及びその製造方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3485872A1 (en) * | 2017-11-15 | 2019-05-22 | Jennifer Peters | Compositions comprising hyaluronic acid and h2 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3602773B2 (ja) | 陽極電解水、及びその製造方法 | |
WO2006030685A1 (ja) | 電解用電極及びこの電解用電極を用いた水酸化第四アンモニウム水溶液の製造方法 | |
WO2004050563A1 (ja) | 還元水及びその製造方法 | |
JP2009270188A (ja) | 高純度水酸化リチウムの製造方法 | |
JP2004351399A (ja) | 還元水及びその製造方法 | |
JP2008110342A (ja) | ブラウンガスを利用した還元水素水製造装置、還元水素水製造方法および還元水素飲料製造装置並びに還元水素飲料製造方法 | |
WO2006064539A1 (ja) | 還元性生理食塩水及びその製造方法 | |
WO2004076363A1 (ja) | 混合電解水の製造方法 | |
JP2007224328A (ja) | アルカリエッチング液のアルカリ回収方法 | |
WO2006061880A1 (ja) | 還元性化粧水及びその製造方法 | |
CN110106545A (zh) | 镍钛合金电化学抛光液、表面处理方法及左心耳封堵器 | |
JP2004329188A (ja) | 還元性茶及びその製造方法 | |
JP2004346053A (ja) | 還元性化粧水及びその製造方法 | |
TW201031604A (en) | Electrodialysis method for purifying of silicate-containing potassium hydroxide etching solution | |
WO2006051588A1 (ja) | 還元性飲料及びその製造方法 | |
CN106517445B (zh) | 一种电穿孔电极结构的制备方法及应用 | |
WO2006082655A1 (ja) | 還元性の香水及びその製造方法 | |
JP2005053882A (ja) | 還元性生理食塩水及びその製造方法 | |
JPS5967379A (ja) | 塩化カリウム水溶液の電解方法 | |
JP2015016414A (ja) | 還元水生成装置 | |
US20190192557A1 (en) | Hypochlorite compositions for the treatment of traumatic brain injury | |
EP1849749A1 (en) | Reducing ice and process for producing reducing liquid with use of the ice | |
JP2005087193A (ja) | 還元性発酵乳及びその製造方法 | |
TWI652229B (zh) | 富氫水生成裝置及其方法 | |
JP5136883B2 (ja) | 金イオン含有水の製造方法および製造装置 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 04806962 Country of ref document: EP Kind code of ref document: A1 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 4806962 Country of ref document: EP |